Loading
TMSB4X (Thymosin beta-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
Plays an important role in the organisation of the cytoskeleton. Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerisation. Potent inhibitor of bone marrow derived stem cell differentiation.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 6 cohorts (1 activating, 5 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
In plain words · TMSB4X (Thymosin beta-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
TMSB4X (Thymosin beta-4) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
Plays an important role in the organisation of the cytoskeleton. Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerisation.
No product in this corpus aims at TMSB4X yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA TMSB4X: RNA low tissue specificity; high antibody staining in 1 normal tissue. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 1 specific cancer type at or above 0.5 (diffuse large B-cell lymphoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P62328; CIViC gene TMSB4X; IntOGen TMSB4X; Human Protein Atlas TMSB4X tissue; Open Targets ENSG00000205542 associations
First described 1984. Earliest sequence paper UniProt cites for the protein: Friedman R.L. et al, Cell, 1984, "Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells". Source.
Sources: HGNC HGNC:11881 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P62328 (protein name, function text, keywords and locations (REST API)); CIViC gene TMSB4X (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000205542 (per-cancer scores at or above 0.5: diffuse large B-cell lymphoma 0.53, non-Hodgkin lymphoma 0.58 (GraphQL API, CC0)); IntOGen TMSB4X (driver in 6 cohorts (Act 1, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Plays an important role in the organisation of the cytoskeleton. Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerisation. Potent inhibitor of bone marrow derived stem cell differentiation. Acts by inhibits the entry of haematopoietic pluripotent stem cells into the S-phase. Location: Cytoplasm, cytoskeleton (UniProt). Locus Xp22.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Appendix, Caudate, Cerebral cortex, Colon, Gallbladder, Lung, Lymph node, Seminal vesicle.
No cancer stained high; medium in colorectal cancer, liver cancer, lung cancer, lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TMSB4X" OR ABSTRACT:"TMSB4X" OR TITLE:"thymosin beta 4 X-linked" OR ABSTRACT:"thymosin beta 4 X-linked" OR TITLE:"Thymosin beta-4" OR ABSTRACT:"Thymosin beta-4" OR TITLE:"TB4X" OR ABSTRACT:"TB4X" OR TITLE:"TMSB4" OR ABSTRACT:"TMSB4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TMSB4X, not a curated reading list.